CRL vs. GSK: Charles River Laboratories vs. GSK Stock Comparison

Company Profile

Charles River Laboratories (CRL) and GSK (GSK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but CRL is classified in Life Sciences Tools & Services while GSK is classified in Pharmaceuticals.

Charles River Laboratories (CRL) trades as ordinary local shares, while GSK (GSK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Charles River Laboratories (CRL) has an aggressive beta of 1.33, indicating higher sensitivity to broad-market moves, while GSK (GSK) is defensive at 0.31 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

GSK (GSK) at 28.27% sits in the top ROE quartile, while Charles River Laboratories (CRL) at 1.27% is closer to the peer norm — stronger capital efficiency for GSK.

GSK (GSK) at 12.97% retains a top-quartile share of revenue as profit, ahead of Charles River Laboratories (CRL) at 1.01%, which keeps about the industry-typical share.

Both Charles River Laboratories (CRL) at 23.42% and GSK (GSK) at 32.14% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

GSK (GSK) at 4.11% is around its peer norm for revenue growth, while Charles River Laboratories (CRL) at -0.85% drops into the bottom quartile, signaling weaker demand or pricing momentum.

GSK (GSK) at 123.15% sits in the top EPS growth quartile, while Charles River Laboratories (CRL) at -1,555.00% falls below its industry range — a large difference in per-share earnings trajectories.

Growth Metrics

Financial Strength

Both Charles River Laboratories (CRL) at 1.41 and GSK (GSK) at 0.86 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Charles River Laboratories (CRL) at 0.87 and GSK (GSK) at 1.30 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

Charles River Laboratories (CRL) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a yield of 1.57%, ranking against industry peers normally.

Charles River Laboratories (CRL) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a payout of 63.33%, ranking against industry peers normally.

Dividend Metrics

Valuation

GSK (GSK) at 17.54 is near its industry’s usual P/E ratio, while Charles River Laboratories (CRL) at 366.87 sits above its peer range — an unusually expensive price for CRL’s trailing earnings.

GSK (GSK) at 3.01 sits in the cheaper P/S ratio quartile while Charles River Laboratories (CRL) at 4.07 prices around its industry’s middle — GSK costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Charles River Laboratories (CRL) at 5.01 and GSK (GSK) at 4.02 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics